The use of HER2 modulation in the adjuvant setting

Current Oncology Reports

Volumn 9, Issue 1, 2007, Pages 9-16

  Johnson, Peter H ^b   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; EARLY CANCER; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SURVIVAL RATE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; HUMANS; RECEPTOR, ERBB-2;

EID: 33846128126     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02951420     Document Type: Review

References (28)

1. Jemal AR, Siegel E, Ward, et al.: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106-130.
2. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4:361-370.
3. Slamon DJ, Clark GM, Wong SG, et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987,235:177-182.
4. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989,244:707-712.
5. Carter P, Presta L, Gorman CM, et al.: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89:4285-4289.
6. Slamon DJ, Leyland-Jones B, Shak S, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
7. Marty M, Cognetti F, Maraninchi D, et al.: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel. in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
8. Vogel CL., Cobleigh MA, Tripathy D, et al.: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
9. Baselga J, Carbonell X, Castaneda-Soto NJ, et al.: Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005, 23:2162-2171.
10. Romond EH, Perez EA, Bryant J, et al.: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
11. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
12. Slamon D, Eiermann W, Robert N, et al.: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005, 94:S5a.
13. Joensuu H, K.-L.P.-L., Bono P, et al.: Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer Trial. N Engl J Med 2006, 354:809-820.
14. Perez E: Special session: Monoclonal antibody therapy in breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005.
15. Smith IE, on behalf of the HERA study team: Scientific special session: Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA trial): disease-free and overall survival after 2 year median follow-up. Presented at the American Society of Clinical Oncology Annual Meeting, 2006.
16. Pegram M, Hsu S, Lewis G, et al.: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999,18:2241-2251.
17. Pegram, MD, O'Callaghan C: Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations. Clin Breast Cancer 2001, 2(Suppl 1):S15-S19.
18. Pegram MD, Lopez A, Konecny G, Slamon DJ: Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol 2000,27-21-25; discussion 92-100.
19. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. N Engl J Med 2005, 353:1734-1736.
20. Bendell JC, Domchek SM, Burstein HJ, et al.: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97.-2972-2977.
21. Hurley, J, Doliny P, Reis I, et al.: Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006, 24:1831-1838.
22. Buzdar AU, Ibrahim NK, Francis D, et al.: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005, 23-3676-3685.
23. Seidman A, Hudis C, Pierri MK, et al.: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002,20:1215-1221.
24. Perez EA, Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004, 22:322-329.
25. Tan-Chiu E, Yothers G, Romond E, et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
26. Crone SA, Zhao YY, Fan L, et al.: ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465.
27. Chien KR: Herceptin and the heart - a molecular modifier of cardiac failure. N Engl J Med 2006, 354:789-790.
28. Guarneri V, Lenihan D, Valero V, et al.: Long term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006 24:4107-4115.